Gan serves as vice president, head of biology at Curie Therapeutics. Prior to joining Curie, Gan was senior director, biology at Blueprint Medicines where he led new target discovery, championed academic collaboration, and initiated or oversaw multiple drug discovery programs. Before Blueprint, Gan was at Forma Therapeutics, Warp Drive Bio, Aveo Oncology, Infinity Pharmaceuticals, and Horst-ARIAD Genomics Center where he held roles of increasing responsibility across target validation, translational research and small molecule and antibody drug discovery. Gan holds a B.S. in genetics and genetic engineering from Fudan University, an M.A. in biology from Mount Holyoke College, a Ph.D. in molecular biology from the University of Pennsylvania, and completed his postdoctoral training at the Howard Hughes Medical Institute at UCLA.